KCT0003126
Recruiting
未知
Clinical study to evaluate the effects and safety of Panax Ginseng Mayer extract and red ginseng to body temperature
Kyung Hee University Hospital0 sites180 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kyung Hee University Hospital
- Enrollment
- 180
- Status
- Recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Subjects who agree to participate in this study and have given their written informed consent
- •2\) Men and women aged 20 to under 65, excluding an illiterate
Exclusion Criteria
- •1\) Present or previous significant allergy to any health supplements and medicine, including ginseng
- •2\) History or presence of any clinically significant medical condition such as dementia, brain tumor, hydrocephalus.
- •3\) History or presence of clinically significant medical condition such as stroke, heart disease (heart failure, angina, myocardial infarction), malignant disease, narrow angle glaucoma, resistant hypertension, lung disease.
- •4\) Subjects who have clinical manifestation associated renal or hepatic disorders (serum creatinine \> 2\.0 mg/dL, liver function test: ALT, AST \> 2\.5 times of the upper limit of normal range)
- •5\) Subjects who show the following results;
- •\- Fasting blood glucose ? 160 mg/dL, despite of taking oral antidiabetic agents
- •\- Platelet ? 150,000/mm3, WBC ? 4,000/mm3, Hemoglobin ? 9\.5 g/dL for men or ? 9\.0 g/dL for women
- •6\) Use of the medications or products such as oral steroid, hormones within 3 months prior to the scheduled study drug administration.
- •7\) Subjects who have been taking medication or functional food, known to interfere with the absorption, metabolism and elimination of study drug (test food) or Subjects who participated in any other clinical trial within 3 months prior to the scheduled study drug administration
- •8\) Subjects who have undergone surgical procedures within 6 months prior to the scheduled study drug administration or who have are taking medications such as herbal supplements (ginseng) or herbal medicine within 1 months prior to the scheduled study drug administration
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasisPsoriasisJPRN-jRCT2080220313Mitsubishi Tanabe Pharma Corporation
Completed
Phase 3
result of vitimelin tablet and vitimelin oil in vitiligoHealth Condition 1: L80- VitiligoCTRI/2021/04/033014DrVasishths Ayuremedies30
Completed
Phase 2
A study for Under eye dark circlesCTRI/2022/09/045732Transformative Learning Solutions Pvt Ltd32
Active, not recruiting
Not Applicable
Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults. - N/AEUCTR2005-003552-35-DEOctapharma AG116
Completed
Phase 2
Clinical study on Dabur gel in reduction of oral malodor.Health Condition 1: R196- HalitosisCTRI/2021/07/034750Dabur India limited161